Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 113Breast Neoplasms 113Ovarian Neoplasms 69Triple Negative Breast Neoplasms 56Endometrial Neoplasms 42Fallopian Tube Neoplasms 40Squamous Cell Carcinoma of Head and Neck 39Lung Neoplasms 38Neoplasm Metastasis 35Stomach Neoplasms 28Parkinson Disease 4, Autosomal Dominant Lewy Body 27Neoplasms 27Esophageal Neoplasms 22Esophageal Squamous Cell Carcinoma 21Head and Neck Neoplasms 16Uterine Cervical Neoplasms 15Carcinoma, Ovarian Epithelial 15Carcinoma 15Colorectal Neoplasms 14Carcinoma, Squamous Cell 11Adenocarcinoma 10Small Cell Lung Carcinoma 9Adenocarcinoma Of Esophagus 9Peritoneal Neoplasms 8Oropharyngeal Neoplasms 8Melanoma 8Carcinoma, Transitional Cell 8Urinary Bladder Neoplasms 7Pancreatic Neoplasms 7Mouth Neoplasms 7

Interventions

Etoposide 3Carboplatin 3atezolizumab 2Cisplatin 2tislelizumab 1obinutuzumab 1lutetium Lu 177 dotatate 1durvalumab 1ceralasertib 1Paclitaxel 1Injections 1EC regimen 1Drug Therapy 1AMG 757 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Extensive Stage Small Cell Lung Cancer × Paclitaxel × 1 year × Clear all
NCT06016270 2025-09-05

A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer

STCube, Inc.

Phase 1/2 Terminated
10 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡